Experience

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised ADC Therapeutics SA in connection with its entry into a facility agreement with Deerfield Partners, L.P., pursuant to which Deerfield agreed to extend senior secured…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering of $850 million aggregate principal amount of 6.250% senior notes due…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Energizer Holdings, Inc. of an additional $250 million aggregate…

Davis Polk advised the representative of the several underwriters in connection with the public offering of $140 million of Class A common stock of Shake Shack Inc. Shake Shack is listed on…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Shake Shack Inc. of shares of its Class A common stock for up to a maximum offering…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies…